931 related articles for article (PubMed ID: 26627013)
61. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
[TBL] [Abstract][Full Text] [Related]
62. Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML.
Morgado-Palacin I; Day A; Murga M; Lafarga V; Anton ME; Tubbs A; Chen HT; Ergan A; Anderson R; Bhandoola A; Pike KG; Barlaam B; Cadogan E; Wang X; Pierce AJ; Hubbard C; Armstrong SA; Nussenzweig A; Fernandez-Capetillo O
Sci Signal; 2016 Sep; 9(445):ra91. PubMed ID: 27625305
[TBL] [Abstract][Full Text] [Related]
63. shRNA screening identifies JMJD1C as being required for leukemia maintenance.
Sroczynska P; Cruickshank VA; Bukowski JP; Miyagi S; Bagger FO; Walfridsson J; Schuster MB; Porse B; Helin K
Blood; 2014 Mar; 123(12):1870-82. PubMed ID: 24501218
[TBL] [Abstract][Full Text] [Related]
64. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
Garrido Castro P; van Roon EHJ; Pinhanços SS; Trentin L; Schneider P; Kerstjens M; Te Kronnie G; Heidenreich O; Pieters R; Stam RW
Leukemia; 2018 Feb; 32(2):323-331. PubMed ID: 28690313
[TBL] [Abstract][Full Text] [Related]
65. Histone Acetyltransferase Activity of MOF Is Required for
Valerio DG; Xu H; Chen CW; Hoshii T; Eisold ME; Delaney C; Cusan M; Deshpande AJ; Huang CH; Lujambio A; Zheng YG; Zuber J; Pandita TK; Lowe SW; Armstrong SA
Cancer Res; 2017 Apr; 77(7):1753-1762. PubMed ID: 28202522
[TBL] [Abstract][Full Text] [Related]
66. H3K79 methylation profiles define murine and human MLL-AF4 leukemias.
Krivtsov AV; Feng Z; Lemieux ME; Faber J; Vempati S; Sinha AU; Xia X; Jesneck J; Bracken AP; Silverman LB; Kutok JL; Kung AL; Armstrong SA
Cancer Cell; 2008 Nov; 14(5):355-68. PubMed ID: 18977325
[TBL] [Abstract][Full Text] [Related]
67. Relatively favorable prognosis for MLL-rearranged childhood acute leukemia with reciprocal translocations.
Yang L; Ding L; Liang J; Chen J; Tang Y; Xue H; Gu L; Shen S; Li B; Chen J
Pediatr Blood Cancer; 2018 Oct; 65(10):e27266. PubMed ID: 29943896
[TBL] [Abstract][Full Text] [Related]
68. SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia.
Chu Y; Chen Y; Guo H; Li M; Wang B; Shi D; Cheng X; Guan J; Wang X; Xue C; Cheng T; Shi J; Yuan W
Oncogene; 2020 Dec; 39(50):7239-7252. PubMed ID: 33037410
[TBL] [Abstract][Full Text] [Related]
69. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
[TBL] [Abstract][Full Text] [Related]
70. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.
Thomas D; Powell JA; Vergez F; Segal DH; Nguyen NY; Baker A; Teh TC; Barry EF; Sarry JE; Lee EM; Nero TL; Jabbour AM; Pomilio G; Green BD; Manenti S; Glaser SP; Parker MW; Lopez AF; Ekert PG; Lock RB; Huang DC; Nilsson SK; Récher C; Wei AH; Guthridge MA
Blood; 2013 Aug; 122(5):738-48. PubMed ID: 23775716
[TBL] [Abstract][Full Text] [Related]
71. Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia.
Cermáková K; Tesina P; Demeulemeester J; El Ashkar S; Méreau H; Schwaller J; Rezáčová P; Veverka V; De Rijck J
Cancer Res; 2014 Sep; 74(18):5139-51. PubMed ID: 25082813
[TBL] [Abstract][Full Text] [Related]
72. Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.
Bates DJ; Salerni BL; Lowrey CH; Eastman A
Cancer Biol Ther; 2011 Aug; 12(4):314-25. PubMed ID: 21768777
[TBL] [Abstract][Full Text] [Related]
73. Dinaciclib potently suppresses MCL-1 and selectively induces the cell death in human iPS cells without affecting the viability of cardiac tissue.
Alsayegh K; Matsuura K; Sekine H; Shimizu T
Sci Rep; 2017 Mar; 7():45577. PubMed ID: 28361959
[TBL] [Abstract][Full Text] [Related]
74. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia.
Prange KHM; Mandoli A; Kuznetsova T; Wang SY; Sotoca AM; Marneth AE; van der Reijden BA; Stunnenberg HG; Martens JHA
Oncogene; 2017 Jun; 36(23):3346-3356. PubMed ID: 28114278
[TBL] [Abstract][Full Text] [Related]
75. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Fiskus W; Boettcher S; Daver N; Mill CP; Sasaki K; Birdwell CE; Davis JA; Takahashi K; Kadia TM; DiNardo CD; Jin Q; Qi Y; Su X; McGeehan GM; Khoury JD; Ebert BL; Bhalla KN
Blood Cancer J; 2022 Jan; 12(1):5. PubMed ID: 35017466
[TBL] [Abstract][Full Text] [Related]
76. MLL-Rearranged Acute Lymphoblastic Leukemia.
El Chaer F; Keng M; Ballen KK
Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
[TBL] [Abstract][Full Text] [Related]
77. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis.
Zhang X; Zheng X; Yang H; Yan J; Fu X; Wei R; Xu X; Zhang Z; Yu A; Zhou K; Ding J; Geng M; Huang X
Cancer Lett; 2018 Sep; 431():150-160. PubMed ID: 29857126
[TBL] [Abstract][Full Text] [Related]
78. MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.
Stavropoulou V; Kaspar S; Brault L; Sanders MA; Juge S; Morettini S; Tzankov A; Iacovino M; Lau IJ; Milne TA; Royo H; Kyba M; Valk PJM; Peters AHFM; Schwaller J
Cancer Cell; 2016 Jul; 30(1):43-58. PubMed ID: 27344946
[TBL] [Abstract][Full Text] [Related]
79. Aberrant TRPM4 expression in MLL-rearranged acute myeloid leukemia and its blockade induces cell cycle arrest via AKT/GLI1/Cyclin D1 pathway.
Wang F; Wu P; Gong S; Chen Y; Gao J; Wang S; Shen Q; Tao H; Hua F; Zhou Z; Zou Z; Ma T; Jia Y
Cell Signal; 2020 Aug; 72():109643. PubMed ID: 32320859
[TBL] [Abstract][Full Text] [Related]
80. Integrated transcriptomic and epigenetic data analysis identifiesaberrant expression of genes in acute myeloid leukemia with MLL‑AF9 translocation.
Wang F; Li Z; Wang G; Tian X; Zhou J; Yu W; Fan Z; Dong L; Lu J; Xu J; Zhang W; Liang A
Mol Med Rep; 2020 Feb; 21(2):883-893. PubMed ID: 31789407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
